Search Results
Philip Mease 3
5 Questions on Tofacitinib/PsA FDA Hearing - Dr. Philip Mease
Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2
Philip Mease, MD: Treatments for Psoriatic Arthritis
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, trial in psoriatic arthritis
Dr. Philip Mease on Late Breaking: Risankizumab in Psoriatric Arthritis
Axial Psoriatic Arthritis - Philip Mease, MD
EULAR 2017 highlights | Philip Mease
Philip Mease, MD: Guselkumab Effective for Psoriatic Arthritis
Optimizing Outcomes Throughout the Journey of Patients With Psoriatic Arthritis
Clinical Assessment and Principles of Management of Psoriatic Arthritis
Researcher comment: SELECT-PsA-2 | Philip Mease